Concepedia

Author

Luc Truyen

Johnson & Johnson (United States)

Also Known As

Luc Truyen

29

Publications

1.1K

Citations

13

H-Index

29

Concepts

All Affiliations

Johnson & Johnson (United States)Vrije Universiteit AmsterdamAmsterdam UMC Location Vrije Universiteit AmsterdamJanssen (Belgium)
LT

About

Luc Truyen is an author at Johnson & Johnson (United States) specializing in medicine, neurology, and neuroscience.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

409

2

Neurology

5

5

397

3

Social Sciences

2

2

127

4

Health Sciences

1

1

11

5

Hepatology

1

1

12

Luc Truyen

×

11

Publications

812

Citations

11

H-Index

YearCitations

A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer???s Disease

Gordon Wilcock, Ian Howe, Hilary Coles,

Drugs & Aging

2003

212

The Cognitive Benefits of Galantamine Are Sustained for at Least 36 Months

Murray A. Raskind, Elaine R. Peskind, Luc Truyen,

Archives of Neurology

2004

165

Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease

Henry Brodaty, Jody Corey‐Bloom, Felix Potocnik,

Dementia and Geriatric Cognitive Disorders

2005

119

Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study

Rutger Goekoop, Serge A.R.B. Rombouts, Cees Jonker,

NeuroImage

2004

108

Development of Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Images in Multiple Sclerosis

Marianne A.A. van Walderveen, Luc Truyen, Bob W. van Oosten,

Archives of Neurology

1999

69

Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions

Jan Hein T. van Waesberghe, Jonas A. Castelijns, Philip Scheltens,

Magnetic Resonance Imaging

1997

47

Pharmacokinetics and Safety of Galantamine in Subjects with Hepatic Impairment and Healthy Volunteers

Qinying Zhao, Ganesh R. Iyer, Tom Verhaeghe,

The Journal of Clinical Pharmacology

2002

25

Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers

Qinying Zhao, Luc Janssens, Tom Verhaeghe,

Current Medical Research and Opinion

2005

25

P4-161 Impact of APOE genotype on the efficacy of galantamine for the treatment of mild cognitive impairment

Michael Gold, Stephan Francke, Jeffrey S. Nye,

Neurobiology of Aging

2004

19

Pharmacokinetics and Safety of Galantamine in Subjects with Hepatic Impairment and Healthy Volunteers

Qinying Zhao, Ganesh R. Iyer, Tom Verhaeghe,

The Journal of Clinical Pharmacology

2002

12

Page 1